how big is Sanofi India?

As of Jun 06, Sanofi India Ltd has a market capitalization of 14,183.29 Cr and reported net sales of 2,038.30 Cr and net profit of 396.20 Cr over the latest four quarters. Shareholder's funds are 860.60 Cr, with total assets of 1,611.70 Cr as of Dec'24.

Market Cap: Sanofi India Ltd has a market capitalization of 14,183.29 Cr and is classified as a Mid Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 2,038.30 Cr. The sum of Net Profit for the same quarters is 396.20 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the reporting period of Dec'24. The Shareholder's Funds amount to 860.60 Cr, and the Total Assets are valued at 1,611.70 Cr.

Who are the peers of the Sanofi India?

Sanofi India's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sanofi India has excellent management risk but below-average growth and the lowest 1-year return at -28.96% among its peers.

Peers: The peers of Sanofi India are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alivus Life, Granules India, Sanofi Consumer, Marksans Pharma, and Ami Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alivus Life, Granules India, Marksans Pharma, and the rest. Below Average growth is noted for Divi's Lab., Torrent Pharma, Sanofi India, Alivus Life, Granules India, and the rest, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Sanofi India, Alivus Life, Granules India, Marksans Pharma, and the rest, while Good capital structure is noted at Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ami Organics at 86.50%, while Sanofi India has the lowest at -28.96%. Sanofi India's return is significantly lower than all peers. Additionally, the six-month return is negative for Torrent Pharma, Sanofi India, and Marksans Pharma.

Who are in the management team of Sanofi India?

As of December 2022, the management team of Sanofi India includes Aditya Narayan (Chairman), Vaibhav Karandikar (CFO), Rodolfo Hrosz (Managing Director), and several independent directors, among others, overseeing the company's governance and operations.

As of December 2022, the management team of Sanofi India includes the following individuals:<BR><BR>1. Aditya Narayan - Chairman & Independent Director<BR>2. Usha Thorat - Independent Director<BR>3. Vaibhav Karandikar - Whole Time Director & CFO<BR>4. Rahul Bhatnagar - Independent Director<BR>5. Marc-Antoine Lucchini - Director<BR>6. Annapurna Das - Director<BR>7. Rodolfo Hrosz - Managing Director<BR>8. Radhika Shah - Company Secretary<BR>9. Renee Amonkar - Whole Time Director & Additional Director<BR><BR>Each member plays a significant role in the governance and operational oversight of the company.

What does Sanofi India do?

Sanofi India Ltd is a multinational pharmaceutical and biotechnology company engaged in manufacturing and trading drugs. As of March 2025, it reported net sales of ₹5,359 Cr and a net profit of ₹1,195 Cr, with a market cap of ₹13,772 Cr.

Overview: <BR>Sanofi India Ltd is a leading multinational company in the Pharmaceuticals & Biotechnology industry, primarily engaged in the manufacturing and trading of drugs and pharmaceuticals.<BR><BR>History: <BR>Sanofi India Limited was incorporated in May 1956 and was previously known as Aventis Pharma Limited. The company changed its name to Sanofi India Limited on May 11, 2012. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 5,359 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,195 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 13,772 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.96% <BR>Debt-Equity: -0.32 <BR>Return on Equity: 43.97% <BR>Price to Book: 15.98<BR><BR>Contact Details: <BR>Address: Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai Mumbai Maharashtra : 400072 <BR>Tel: 91-22-28032000 <BR>Email: igrc.sil@sanofi.com <BR>Website: http://www.sanofiindialtd.com

Who are the top shareholders of the Sanofi India?

The top shareholders of Sanofi India include Hoechst Gmbh with 60.37%, Life Insurance Corporation of India - P & Gs Fund with 5.95%, mutual funds with 11.26%, foreign institutional investors at 5.57%, and individual investors holding 8.38%.

The top shareholders of Sanofi India include Hoechst Gmbh, which holds a significant 60.37% of the shares, making it the largest promoter. Other notable shareholders include the Life Insurance Corporation of India - P & Gs Fund, with a holding of 5.95%. Additionally, mutual funds collectively hold 11.26% through 18 schemes, while foreign institutional investors (FIIs) account for 5.57% through 134 entities. Individual investors also have a stake, holding 8.38% of the shares.

Is Sanofi India technically bullish or bearish?

As of August 12, 2025, Sanofi India has shifted to a bearish technical trend, supported by negative indicators like MACD, Bollinger Bands, and KST, alongside a significant -24.37% return over the past year compared to the Sensex.

As of 12 August 2025, the technical trend for Sanofi India has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish outlook in the same periods. Daily moving averages confirm a bearish trend. The KST is bearish on both weekly and monthly charts, while Dow Theory and OBV indicate a mildly bearish stance on the weekly and monthly time frames. Overall, the strength of the bearish trend is reinforced by the significant negative returns compared to the Sensex across various periods, particularly a -24.37% return over the past year.

Is Sanofi India overvalued or undervalued?

As of August 26, 2025, Sanofi India is fairly valued with a PE ratio of 33.02, an EV to EBITDA of 22.78, and a ROE of 41.43%, showing better valuation compared to peers like Sun Pharma and Divi's Lab, despite underperforming against the Sensex with a year-to-date return of -16.18%.

As of 26 August 2025, the valuation grade for Sanofi India has moved from expensive to fair. Based on the analysis, the company is currently fairly valued. Key ratios include a PE ratio of 33.02, an EV to EBITDA of 22.78, and a ROE of 41.43%. <BR><BR>In comparison to its peers, Sanofi India's PE ratio is slightly lower than Sun Pharma's at 33.48, while it is significantly more favorable than Divi's Lab, which stands at 71.33. Additionally, the PEG ratio for Sanofi is 0.00, indicating a potential for growth relative to its price. Notably, the stock has underperformed against the Sensex over various time frames, with a year-to-date return of -16.18% compared to the Sensex's 3.39%, reinforcing the view that it is fairly valued in the current market context.

When is the next results date for Sanofi India?

Sanofi India will announce its results on 29 October 2025.

Sanofi India will declare its results on 29 October 2025.

Are Sanofi India latest results good or bad?

Sanofi India's latest results are mixed; while net profit increased by 11.07% quarter-on-quarter, it fell 45.89% year-on-year, raising concerns about profitability. Despite stable operating margins and strong return on equity, the overall outlook appears more negative due to significant earnings challenges.

Sanofi India's latest results present a mixed picture. In Q2 FY26, the company reported a net profit of ₹82.20 crores, which is an 11.07% increase compared to the previous quarter. However, this figure represents a significant decline of 45.89% year-on-year, indicating serious challenges in profitability.<BR><BR>On the sales front, net sales for the quarter were ₹524.00 crores, reflecting a slight decrease of 1.74% from the previous quarter, although there was a year-on-year growth of 6.79%. This volatility in revenue is concerning, especially following a previous quarter that showed recovery.<BR><BR>Operating margins remained relatively stable at 22.84%, down slightly from the previous quarter, but still indicative of the company's ability to maintain efficiency in a challenging market. The return on equity is strong at 35.83%, which is among the best in the industry, highlighting effective capital utilization.<BR><BR>Overall, while there are some positive aspects such as sequential profit growth and strong operating margins, the sharp year-on-year decline in net profit raises significant concerns about the company's earnings sustainability. The combination of these factors suggests that the results are more negative than positive, reflecting ongoing struggles in the current market environment.

How has been the historical performance of Sanofi India?

Sanofi India's historical performance for the fiscal years ending December 2023 and 2024 shows slight growth in net sales and operating income, but declines in profitability metrics, including net profit and earnings per share. Total liabilities and assets also decreased, while cash flow from operations improved.

Answer:<BR>The historical performance of Sanofi India shows a mixed trend in its financial metrics for the years ending December 2023 and December 2024.<BR><BR>Breakdown:<BR>In the fiscal year ending December 2024, Sanofi India reported net sales of 2,013.20 crore, a slight increase from 1,996.10 crore in December 2023. Total operating income also rose to 2,013.20 crore from 1,996.10 crore. However, total expenditure increased to 1,522.40 crore from 1,508.40 crore, leading to an operating profit (PBDIT) of 507.30 crore, down from 548.90 crore the previous year. Profit before tax decreased to 431.40 crore from 528.50 crore, and profit after tax fell to 313.70 crore from 364.60 crore. The consolidated net profit also declined to 413.30 crore from 602.90 crore. Earnings per share dropped to 179.7 from 262.13, reflecting a decrease in profitability. On the balance sheet, total liabilities decreased to 1,611.70 crore from 1,714.80 crore, while total assets also fell to 1,611.70 crore from 1,714.80 crore. Cash flow from operating activities improved to 461.00 crore from 230.00 crore, but cash and cash equivalents at year-end decreased to 283.00 crore from 394.00 crore. Overall, while sales and operating income showed slight growth, profitability metrics and cash reserves reflected a downturn.

Should I buy, sell or hold Sanofi India?

Has Sanofi India declared dividend?

Yes, Sanofi India Ltd has declared a dividend of 750% (₹117 per share) with an ex-date of November 7, 2025. Despite the dividend, the company's stock has shown negative total returns across various periods, indicating challenges in performance.

Sanofi India Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 750%<BR>- Amount per share: 117<BR>- Ex-date: 07 Nov 25<BR><BR>Dividend Yield: 2.47%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -18.68%, the dividend return was 1.35%, resulting in a total return of -17.33%.<BR><BR>Over the past 6 months, the price return was -18.91%, the dividend return was 1.28%, leading to a total return of -17.63%.<BR><BR>For the 1-year period, the price return was -26.88%, with a dividend return of 2.88%, culminating in a total return of -24.0%.<BR><BR>In the 2-year period, the price return was -35.48%, the dividend return was 4.63%, resulting in a total return of -30.85%.<BR><BR>During the last 3 years, the price return was -13.85%, the dividend return was 9.68%, leading to a total return of -4.17%.<BR><BR>Over the 4-year period, the price return was -42.23%, with a dividend return of 12.88%, resulting in a total return of -29.35%.<BR><BR>In the 5-year period, the price return was -40.07%, the dividend return was 15.46%, culminating in a total return of -24.61%.<BR><BR>Overall, while Sanofi India has declared a substantial dividend, the total returns over various periods indicate a trend of negative performance, particularly in price returns, suggesting challenges in the company's stock performance despite the dividend payouts.

Which are the latest news on Sanofi India?

Why is Sanofi India falling/rising?

As of 04-Dec, Sanofi India Ltd's stock price is at 4,379.85, reflecting a decline of 13.7 (-0.31%) and significant underperformance over various time frames, including a year-to-date drop of 28.19%. The stock is trading below key moving averages, indicating a bearish trend, and despite a high dividend yield, negative sentiment persists due to poor long-term growth prospects.

As of 04-Dec, Sanofi India Ltd's stock price is falling, currently at 4,379.85, reflecting a decrease of 13.7 (-0.31%). This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, including a year-to-date drop of 28.19% compared to a 9.12% increase in the Sensex. Over the past year, the stock has generated a return of -30.68%, indicating poor performance relative to the market.<BR><BR>Today's performance shows that the stock has underperformed its sector by 0.6% and has experienced a trend reversal after two consecutive days of gains. Additionally, it is trading below all key moving averages, which suggests a bearish trend. Despite a rise in delivery volume by 14.82% against the 5-day average, the overall sentiment remains negative due to the company's poor long-term growth prospects, with net sales and operating profit declining at annual rates of -8.47% and -5.55%, respectively, over the last five years.<BR><BR>Moreover, the stock's high dividend yield of 4.39% and fair valuation compared to peers do not seem to be enough to offset the negative sentiment stemming from its flat results and below-par performance in both the near and long term. High institutional holdings at 27.86% indicate some confidence, but the overall outlook remains bleak, contributing to the stock's current decline.